Skip to content

Study · Ex vivo tissue · 2017

8 results

Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin.

Pawar K, Kolli CS, Rangari VK, Babu RJ

Journal of pharmaceutical sciences24 Mar 2017Cited by 11 (Europe PMC)

PMID28343991 (opens in a new tab)DOI10.1016/j.xphs.2017.03.017 (opens in a new tab)PepBankPUB-28343991
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabEx vivo tissuePharmacokinetics

    KPV permeation across human skin by simple passive diffusion was below the detection limit of 0.01 μg/mL.

    In plain wordsIn human skin samples, KPV alone did not pass through the skin at a detectable level.

    Peptide
    KPV
    Outcome
    Not applicableKPV permeation by passive diffusion
    Study

    humann: not reported in source

    dermatomed human skin
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · transdermalAs given in this study (human).

    Measurements

    limit of detection
    0.01 µg/mL
    passive diffusion

    Source sentences

    Summary
    KPV permeation was less than detectable levels (limit of detection, 0.01 μg/mL) by simple passive diffusion.
    1 context sentence
    Summary · context
    Present study investigates various transdermal enhancement strategies such as iontophoresis (ITP), microneedles (MN), and their combination (ITP + MN) on KPV delivery across dermatomed human skin.
  2. 02LabEx vivo tissuePharmacokinetics

    Microneedle treatment increased KPV permeation across human skin to 4.4 μg/cm2/h.

    In plain wordsIn human skin samples, microneedle treatment let KPV pass through the skin, compared with none by passive diffusion.

    Peptide
    KPV
    Outcome
    IncreaseKPV permeation rate with microneedles
    Study

    humann: not reported in source

    dermatomed human skin
    Comparator
    Passive diffusion
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · transdermalAs given in this study (human).

    Measurements

    permeation rate
    4.4 µg/cm2/h
    MN

    Source sentences

    Summary
    However, KPV permeation was increased to 4.4 μg/cm2/h by MN treatment.
    1 context sentence
    Summary · context
    Present study investigates various transdermal enhancement strategies such as iontophoresis (ITP), microneedles (MN), and their combination (ITP + MN) on KPV delivery across dermatomed human skin.
  3. 03LabEx vivo tissuePharmacokinetics

    Iontophoresis increased the KPV permeation rate 8 fold compared with microneedles alone.

    In plain wordsIn human skin samples, iontophoresis raised KPV passage 8 times compared with microneedles alone.

    Peptide
    KPV
    Outcome
    IncreaseKPV permeation rate with iontophoresis
    Study

    humann: not reported in source

    dermatomed human skin
    Comparator
    Microneedles alone
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · transdermalAs given in this study (human).

    Measurements

    permeation rate fold increase
    8 fold
    ITP vs MN

    Source sentences

    Summary
    Furthermore, ITP and ITP + MN increased the permeation rate by 8 and 35 fold, respectively, as compared to MN alone.
    1 context sentence
    Summary · context
    Present study investigates various transdermal enhancement strategies such as iontophoresis (ITP), microneedles (MN), and their combination (ITP + MN) on KPV delivery across dermatomed human skin.
  4. 04LabEx vivo tissuePharmacokinetics

    Iontophoresis combined with microneedles increased the KPV permeation rate 35 fold compared with microneedles alone.

    In plain wordsIn human skin samples, iontophoresis plus microneedles raised KPV passage 35 times compared with microneedles alone.

    Peptide
    KPV
    Outcome
    IncreaseKPV permeation rate with iontophoresis plus microneedles
    Study

    humann: not reported in source

    dermatomed human skin
    Comparator
    Microneedles alone
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · transdermalAs given in this study (human).

    Measurements

    permeation rate fold increase
    35 fold
    ITP + MN vs MN

    Source sentences

    Summary
    Furthermore, ITP and ITP + MN increased the permeation rate by 8 and 35 fold, respectively, as compared to MN alone.
    1 context sentence
    Summary · context
    Present study investigates various transdermal enhancement strategies such as iontophoresis (ITP), microneedles (MN), and their combination (ITP + MN) on KPV delivery across dermatomed human skin.
  5. 05LabEx vivo tissuePharmacokinetics

    Microneedles increased KPV skin retention 5 fold compared with passive diffusion.

    In plain wordsIn human skin samples, microneedles raised the amount of KPV kept in the skin 5 times compared with passive diffusion.

    Peptide
    KPV
    Outcome
    IncreaseKPV skin retention with microneedles
    Study

    humann: not reported in source

    dermatomed human skin
    Comparator
    Passive diffusion
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · transdermalAs given in this study (human).

    Measurements

    skin retention fold increase
    5 fold
    MN vs passive diffusion

    Source sentences

    Summary
    The skin retention levels of KPV by MN, ITP, and ITP + MN were increased by 5, 10, and 10 fold, respectively, as compared to passive diffusion.
    1 context sentence
    Summary · context
    Present study investigates various transdermal enhancement strategies such as iontophoresis (ITP), microneedles (MN), and their combination (ITP + MN) on KPV delivery across dermatomed human skin.
  6. 06LabEx vivo tissuePharmacokinetics

    Iontophoresis increased KPV skin retention 10 fold compared with passive diffusion.

    In plain wordsIn human skin samples, iontophoresis raised the amount of KPV kept in the skin 10 times compared with passive diffusion.

    Peptide
    KPV
    Outcome
    IncreaseKPV skin retention with iontophoresis
    Study

    humann: not reported in source

    dermatomed human skin
    Comparator
    Passive diffusion
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · transdermalAs given in this study (human).

    Measurements

    skin retention fold increase
    10 fold
    ITP vs passive diffusion

    Source sentences

    Summary
    The skin retention levels of KPV by MN, ITP, and ITP + MN were increased by 5, 10, and 10 fold, respectively, as compared to passive diffusion.
    1 context sentence
    Summary · context
    Present study investigates various transdermal enhancement strategies such as iontophoresis (ITP), microneedles (MN), and their combination (ITP + MN) on KPV delivery across dermatomed human skin.
  7. 07LabEx vivo tissuePharmacokinetics

    Iontophoresis combined with microneedles increased KPV skin retention 10 fold compared with passive diffusion.

    In plain wordsIn human skin samples, iontophoresis plus microneedles raised the amount of KPV kept in the skin 10 times compared with passive diffusion.

    Peptide
    KPV
    Outcome
    IncreaseKPV skin retention with iontophoresis plus microneedles
    Study

    humann: not reported in source

    dermatomed human skin
    Comparator
    Passive diffusion
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · transdermalAs given in this study (human).

    Measurements

    skin retention fold increase
    10 fold
    ITP + MN vs passive diffusion

    Source sentences

    Summary
    The skin retention levels of KPV by MN, ITP, and ITP + MN were increased by 5, 10, and 10 fold, respectively, as compared to passive diffusion.
    1 context sentence
    Summary · context
    Present study investigates various transdermal enhancement strategies such as iontophoresis (ITP), microneedles (MN), and their combination (ITP + MN) on KPV delivery across dermatomed human skin.
  8. 08LabEx vivo tissuePharmacokinetics

    Confocal imaging showed that FITC-labeled KPV migrated through the stratum corneum, along the microchannels and into lower epidermal tissue, beyond 100 μm depth.

    In plain wordsIn human skin samples, labeled KPV moved through the skin surface layer and into deeper skin.

    Peptide
    KPV
    Outcome
    Not applicableDepth of FITC-labeled KPV penetration
    Study

    humann: not reported in source

    dermatomed human skin
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · transdermalAs given in this study (human).

    Measurements

    penetration depth
    > 100 µm
    FITC-labeled KPV

    Source sentences

    Summary
    Confocal studies indicate that fluorescein isothiocyanate-labeled KPV migrated through the stratum corneum, along the microchannels and into the lower epidermal tissue because the fluorescence was observed beyond the depth of 100 μm.
    1 context sentence
    Summary · context
    Present study investigates various transdermal enhancement strategies such as iontophoresis (ITP), microneedles (MN), and their combination (ITP + MN) on KPV delivery across dermatomed human skin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.